Skip to main content
Premium Trial:

Request an Annual Quote

EPA Licenses Simulations Plus Software for Drug Toxicity Prediction

NEW YORK (GenomeWeb News) – The US Environmental Protection Agency has licensed Simulations Plus’ ADMET Predictor chemical and toxicity software to help monitor potential drug pollutants in the water supply and in oceans, the company said yesterday.
Drugs are a “potential environmental hazard,” said Simulations Plus VP of Marketing and Sales Ron Creeley, “because a large portion of them are thrown away instead of being taken.” When these drugs end up in sewage treatment facilities and landfills they can end up in streams and oceans, he said.
Creeley said that it is now important for the EPA, the chemical industry, and drug manufacturers to “consider not only how new molecules accomplish their designed purpose, but also how the environment could be affected if and when they get into our air or water.”
He also said that this is the first time the EPA has licensed the firm’s software.
Robert Fraczkiewicz, product manager for ADMET Predictor, said the software will “allow the EPA to predict a number of potential toxicities for industry chemicals, agricultural chemicals, and drug molecules plus excipients.”
Fraczkiewicz also said that the software’s Enslein Metabolism Module can be used to determine how people will metabolize chemicals.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.